Cancer Discov. 2018 Feb;8(2):131-132. doi: 10.1158/2159-8290.CD-NB2017-179. Epub 2017 Dec 15.
The phase II JULIET trial suggests that the CD19-targeting CAR T-cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large B-cell lymphoma. Three months after the therapy, 32% of the patients showed complete responses and 6% showed partial responses. After 6 months, those rates were 30% and 7%.
II期JULIET试验表明，靶向CD19的嵌合抗原受体（CAR）T细胞疗法tisagenlecleucel在复发和难治性弥漫性大B细胞淋巴瘤患者中产生了持久的反应。治疗三个月后，32%的患者表现出完全缓解，6%的患者表现出部分缓解。六个月后，这些比率分别为30%和7%。
